The Felsenstein Medical Research Center
TOPIC

Laboratory of Experimental Pharmacology and Oncology

Head of Laboratory: Ada Rephaeli, Ph.D.

  Tel: 972-3-9376126
Fax: 972-3-9228096
E-mail: adarep@post.tau.ac.il
Address: FMRC, Beilinson Campus, Petah Tikva 49100, Israel

Research Topics

  1. The anticancer activity of histone deacetylase (HDAC) inhibitors

  2. The interaction between HDAC-prodrugs and anticancer treatment.

  3. The anticancer activity of formal dehyde prodrugs: mode of action and the basis for their selectivity

  4. Protection of normal cells and organs by HDAC inhibitors.

  5. GABA derivatives uses for the treatment of neurological disorders

Selected Publications

  1. Tarasenko N, Nudelman A, Tarasenko I, Entin-Meer M, Hass-Kogan D, Inbal A, Rephaeli A. Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex).Clin Exp Metastasis, 25:703-16, 2008.

  2. Rephaeli A, Gil-Ad I, Aharoni A, Tarasenko I, Tarasenko N, Geffen Y, Halbfinger E, Nisemblat Y, Weizman A, Nudelman A. Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. J Med Chem. 2009 May 14;52:3010-7. MEDLINE

  3. Berkovitch G, Doron D, Nudelman A, Malik Z, Rephaeli A., Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity independent and dependent on photoactivation J Med Chem 51,7356–7369, 2008 MEDLINE

  4. Geffen Y, Nudelman A, Gil-Ad I, Rephaeli A, Huang M, Savitsky K, Klapper L, Winkler I, Meltzer HY, Weizman A. BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. Eur Neuropsychopharmacol 10:1-13, 2009. MEDLINE

  5. Tarasenko N, Kessler-Icekson G, Boer P, Inbal A, Schlesinger H, Phillips DR, Cutts SM, Nudelman A, Rephaeli A. The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity. Invest New Drugs. 2010 Sep 23. [Epub ahead of print] MEDLINE